UMIN ID: UMIN000053436
Registered date:26/01/2024
Web Questionnaire Survey Study on adverse effects of trifluridine/tipiracil for patients and doctors.
Basic Information
| Recruitment status | Pending |
|---|---|
| Health condition(s) or Problem(s) studied | Colorectal cancer, Gastric cancer |
| Date of first enrollment | 2024/01/29 |
| Target sample size | 250 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | The state of occurrence of adverse effects of trifluridine/tipiracil and the details of supportive care |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 18years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Doctors: 1) Doctors who are external research advisors in this study |
Related Information
| Primary Sponsor | TAIHO PHARMACEUTICAL CO., LTD. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | TAIHO PHARMACEUTICAL CO., LTD. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Haruhiko Seki |
| Address | 13F Ochanomizu SolaCity 4-6 Kanda-Surugadai Chiyoda-ku Tokyo Japan 101-0062 |
| Telephone | 03-5295-1579 |
| haruhiko.seki@intage.com | |
| Affiliation | INTAGE Healthcare Value & Access Department |
| scientific contact | |
| Name | Hironari Iwamoto |
| Address | 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo Japan |
| Telephone | 03-3294-4527 |
| th-ftdtpirwd@taiho.co.jp | |
| Affiliation | TAIHO PHARMACEUTICAL CO., LTD. Medical Affairs Dept. |